Jason S. Morrow

Array ( [id] => 17988745 [patent_doc_number] => 20220354782 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-10 [patent_title] => SUBCUTANEOUSLY INJECTABLE INSULIN AND GLUCAGON FORMULATIONS AND METHODS OF ADMINISTRATION [patent_app_type] => utility [patent_app_number] => 17/760596 [patent_app_country] => US [patent_app_date] => 2020-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14362 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17760596 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16570642 [patent_doc_number] => 20210009648 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => PEPTIDES FOR TREATMENT OF DIABETES [patent_app_type] => utility [patent_app_number] => 17/022526 [patent_app_country] => US [patent_app_date] => 2020-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14508 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17022526 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17981234 [patent_doc_number] => 20220347270 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => EXENATIDE ANALOG [patent_app_type] => utility [patent_app_number] => 17/764041 [patent_app_country] => US [patent_app_date] => 2020-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4025 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17764041 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20480363 [patent_doc_number] => 12528834 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-20 [patent_title] => Method for producing peptide compound [patent_app_type] => utility [patent_app_number] => 17/763185 [patent_app_country] => US [patent_app_date] => 2020-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7129 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17763185 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18019049 [patent_doc_number] => 20220370548 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => NEUROLOGICAL DISEASE TREATMENT WITH COMPLEMENT INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/642096 [patent_app_country] => US [patent_app_date] => 2020-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26629 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -106 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17642096 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18077366 [patent_doc_number] => 20220402978 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-22 [patent_title] => POLYPEPTIDES MIMICKING EPITOPE OF BROADLY NEUTRALIZING ANTIBODY VRC01 AS ANTIGENS FOR A VACCINE PREVENTING HIV-1 INFECTION [patent_app_type] => utility [patent_app_number] => 17/642131 [patent_app_country] => US [patent_app_date] => 2020-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5460 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 150 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17642131 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17929790 [patent_doc_number] => 20220324915 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-13 [patent_title] => MITIGATION OF PERI-IMPLANTITIS BY DESIGN AND STABILITY OF BIFUNCTIONAL PEPTIDES WITH ANTIMICROBIAL PROPERTIES [patent_app_type] => utility [patent_app_number] => 17/641058 [patent_app_country] => US [patent_app_date] => 2020-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14873 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17641058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18434385 [patent_doc_number] => 20230181679 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => OPHTHALMIC COMPOSITION FOR THE TREATMENT OF UVEITIS [patent_app_type] => utility [patent_app_number] => 17/640679 [patent_app_country] => US [patent_app_date] => 2020-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7697 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17640679 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16540982 [patent_doc_number] => 20200407395 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-31 [patent_title] => CHIRAL PEPTIDES [patent_app_type] => utility [patent_app_number] => 17/011264 [patent_app_country] => US [patent_app_date] => 2020-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21151 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17011264 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16525253 [patent_doc_number] => 20200399333 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-24 [patent_title] => HISTATINS AND METHOD OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/011273 [patent_app_country] => US [patent_app_date] => 2020-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8539 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17011273 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20730244 [patent_doc_number] => 12637492 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-05-26 [patent_title] => Peptide inhibitors of focal adhesion kinase activity and uses thereof [patent_app_type] => utility [patent_app_number] => 17/638930 [patent_app_country] => US [patent_app_date] => 2020-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 14 [patent_no_of_words] => 18536 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17638930 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17897029 [patent_doc_number] => 20220306691 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-29 [patent_title] => THERAPEUTIC PEPTIDES [patent_app_type] => utility [patent_app_number] => 17/634499 [patent_app_country] => US [patent_app_date] => 2020-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31100 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17634499 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17895417 [patent_doc_number] => 20220305079 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-29 [patent_title] => THERAPEUTIC PEPTIDES [patent_app_type] => utility [patent_app_number] => 17/634490 [patent_app_country] => US [patent_app_date] => 2020-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31282 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17634490 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16451062 [patent_doc_number] => 20200360488 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-19 [patent_title] => PTH COMPOUNDS WITH LOW PEAK-TO-TROUGH RATIOS [patent_app_type] => utility [patent_app_number] => 16/989225 [patent_app_country] => US [patent_app_date] => 2020-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33612 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16989225 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17867076 [patent_doc_number] => 20220289811 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => A FORMULATION OF INSULIN BASED ON CRYSTAL-SEEDING IN HYDROGELS AND METHOD THEREOF [patent_app_type] => utility [patent_app_number] => 17/635401 [patent_app_country] => US [patent_app_date] => 2020-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3867 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17635401 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17996725 [patent_doc_number] => 11497812 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-15 [patent_title] => Compositions and methods for inhibiting the activity of LAR family phosphatases [patent_app_type] => utility [patent_app_number] => 16/983879 [patent_app_country] => US [patent_app_date] => 2020-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 15 [patent_no_of_words] => 20886 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16983879 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17865478 [patent_doc_number] => 20220288213 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => INSULIN ANALOGUES WITH GLUCOSE REGULATED CONFORMATIONAL SWITCH [patent_app_type] => utility [patent_app_number] => 17/630258 [patent_app_country] => US [patent_app_date] => 2020-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8659 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -51 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17630258 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451506 [patent_doc_number] => 20230192784 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => KLF Induced Cardiomyogenesis [patent_app_type] => utility [patent_app_number] => 17/630263 [patent_app_country] => US [patent_app_date] => 2020-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18333 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17630263 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20622641 [patent_doc_number] => 12590139 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-31 [patent_title] => MHC class II molecules and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/631821 [patent_app_country] => US [patent_app_date] => 2020-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 44 [patent_no_of_words] => 15957 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 129 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17631821 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17775028 [patent_doc_number] => 20220241377 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-04 [patent_title] => RECEPTOR-TARGETING PEPTIDE-DRUG CONJUGATES [patent_app_type] => utility [patent_app_number] => 17/629460 [patent_app_country] => US [patent_app_date] => 2020-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8204 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17629460 [rel_patent_id] =>[rel_patent_doc_number] =>)